Green Cross - Asset Resilience Ratio
Green Cross (005250) has an Asset Resilience Ratio of 0.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Green Cross (005250) total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2024)
This chart shows how Green Cross's Asset Resilience Ratio has changed over time. See Green Cross net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Green Cross's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Green Cross (005250) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩22.22 Billion | 0.52% |
| Total Liquid Assets | ₩22.22 Billion | 0.52% |
Asset Resilience Insights
- Limited Liquidity: Green Cross maintains only 0.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Green Cross Industry Peers by Asset Resilience Ratio
Compare Green Cross's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO |
Biotechnology | 11.59% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS |
Biotechnology | 0.58% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
BioArctic AB (publ)
ST:BIOA-B |
Biotechnology | 72.35% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Green Cross (2000–2024)
The table below shows the annual Asset Resilience Ratio data for Green Cross.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.19% | ₩6.79 Billion ≈ $4.60 Million |
₩3.67 Trillion ≈ $2.49 Billion |
-0.39pp |
| 2023-12-31 | 0.58% | ₩21.57 Billion ≈ $14.62 Million |
₩3.74 Trillion ≈ $2.53 Billion |
-0.30pp |
| 2022-12-31 | 0.87% | ₩31.34 Billion ≈ $21.24 Million |
₩3.59 Trillion ≈ $2.43 Billion |
-0.92pp |
| 2021-12-31 | 1.80% | ₩62.83 Billion ≈ $42.58 Million |
₩3.50 Trillion ≈ $2.37 Billion |
-0.13pp |
| 2020-12-31 | 1.92% | ₩62.35 Billion ≈ $42.25 Million |
₩3.24 Trillion ≈ $2.20 Billion |
+0.28pp |
| 2019-12-31 | 1.64% | ₩45.49 Billion ≈ $30.82 Million |
₩2.77 Trillion ≈ $1.88 Billion |
+0.86pp |
| 2018-12-31 | 0.78% | ₩20.53 Billion ≈ $13.91 Million |
₩2.63 Trillion ≈ $1.78 Billion |
+0.66pp |
| 2017-12-31 | 0.12% | ₩3.07 Billion ≈ $2.08 Million |
₩2.56 Trillion ≈ $1.74 Billion |
-3.81pp |
| 2016-12-31 | 3.93% | ₩88.35 Billion ≈ $59.87 Million |
₩2.25 Trillion ≈ $1.52 Billion |
+0.30pp |
| 2015-12-31 | 3.63% | ₩74.66 Billion ≈ $50.59 Million |
₩2.06 Trillion ≈ $1.40 Billion |
-0.28pp |
| 2014-12-31 | 3.90% | ₩69.89 Billion ≈ $47.37 Million |
₩1.79 Trillion ≈ $1.21 Billion |
+1.72pp |
| 2013-12-31 | 2.19% | ₩35.51 Billion ≈ $24.06 Million |
₩1.62 Trillion ≈ $1.10 Billion |
+1.16pp |
| 2012-12-31 | 1.02% | ₩14.81 Billion ≈ $10.03 Million |
₩1.45 Trillion ≈ $980.16 Million |
-0.42pp |
| 2011-12-31 | 1.45% | ₩66.57 Billion ≈ $45.12 Million |
₩4.60 Trillion ≈ $3.12 Billion |
-40.76pp |
| 2010-12-31 | 42.21% | ₩1.74 Trillion ≈ $1.18 Billion |
₩4.11 Trillion ≈ $2.79 Billion |
-0.61pp |
| 2009-12-31 | 42.81% | ₩1.43 Trillion ≈ $970.73 Million |
₩3.35 Trillion ≈ $2.27 Billion |
+27.25pp |
| 2008-12-31 | 15.57% | ₩433.26 Billion ≈ $293.61 Million |
₩2.78 Trillion ≈ $1.89 Billion |
+2.25pp |
| 2007-12-31 | 13.31% | ₩323.75 Billion ≈ $219.40 Million |
₩2.43 Trillion ≈ $1.65 Billion |
-5.38pp |
| 2006-12-31 | 18.69% | ₩376.09 Billion ≈ $254.87 Million |
₩2.01 Trillion ≈ $1.36 Billion |
+2.44pp |
| 2005-12-31 | 16.26% | ₩287.10 Billion ≈ $194.57 Million |
₩1.77 Trillion ≈ $1.20 Billion |
-11.63pp |
| 2004-12-31 | 27.89% | ₩452.30 Billion ≈ $306.52 Million |
₩1.62 Trillion ≈ $1.10 Billion |
+7.50pp |
| 2003-12-31 | 20.39% | ₩326.99 Billion ≈ $221.59 Million |
₩1.60 Trillion ≈ $1.09 Billion |
+9.02pp |
| 2002-12-31 | 11.37% | ₩46.21 Billion ≈ $31.32 Million |
₩406.36 Billion ≈ $275.38 Million |
+4.63pp |
| 2001-12-31 | 6.74% | ₩33.12 Billion ≈ $22.44 Million |
₩491.42 Billion ≈ $333.03 Million |
-3.18pp |
| 2000-12-31 | 9.92% | ₩42.96 Billion ≈ $29.11 Million |
₩432.99 Billion ≈ $293.43 Million |
-- |
About Green Cross
Green Cross Holdings Corporation operates as a biotechnology company. The company provides prescription drugs and over the counter drugs; aseptic fill and finish services for drug manufacturing; and pharmaceutical logistics services. It also researches and develops plasma derivatives for von Willebrand disease and primary immunodeficiency; vaccines for mRNA flu, anthrax, tetanus, diphtheria, pert… Read more